Expression and clinical significance of IL-6 in patients with allergic rhinitis


  • Reshaib Maqsood Department of ENT and HNS, GMC Srinagar, Jammu and Kashmir, India
  • Hanan Iqbal Department of ENT and HNS, GMC Srinagar, Jammu and Kashmir, India
  • Samreen Gul Department of ENT and HNS, GMC Srinagar, Jammu and Kashmir, India
  • Ihsan Ali Department of ENT and HNS, GMC Srinagar, Jammu and Kashmir, India
  • Junaid Malik Department of ENT and HNS, GMC Srinagar, Jammu and Kashmir, India



Allergic rhinitis, Interleukin-6, ARIA


Background: Allergic rhinitis is a chronic inflammatory disease with a high incidence affecting the quality of life of patients. The objective of the study was to explore the expression and clinical significance of IL-6 in patients with allergic rhinitis.

Methods: This cross-sectional analytical study was conducted in the department of ENT, H&NS, Government Medical College, Srinagar. A total of 180 patients were included in the study, out of them 90 patients with allergic rhinitis were cases and 90 patients comprised the control group who did not have allergic rhinitis. The recorded data was compiled and entered in a spreadsheet (Microsoft Excel) and then exported to data editor of SPSS Version 20.0 (SPSS Inc., Chicago, Illinois, USA).

Results: A total of 184 patients participated in the study. The mean age in case group was 35.7±15.46 years compared to control group which was 37.1±12.89 years. There was male dominance in both the groups. Comparison of IL-6 levels as per severity of allergic rhinitis was assessed in this study and it was found that in patients with severe allergic rhinitis the mean IL-6 levels were 65.2±5.32; in moderate, patients had IL-6 levels of 52.8±5.84 and in mild patients had IL-6 levels of 46.7±6.81.

Conclusions: Clinical testing of IL-6 is likely to improve the diagnostic rate of early allergic rhinitis and help in halting the progression of disease and improve the patients prognosis and reduce symptoms and morbidity. Higher the levels of IL_6 more severe will be the allergic rhinitis.


Incorvaia C, Cavaliere C, Frati F. Allergic rhinitis. J Biol Regul Homeost Agents 2018;32:61-6.

Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006; 368(9537):733-43.

Campo P, Eguiluz-Gracia I, Plaza-Serón MC, et al. Bronchial asthma triggered by house dust mites in patients with local allergic rhinitis. Allergy. 2019;74: 1502-10.

Wallace DV, Dykewicz MS. Seasonal Allergic Rhinitis: A focused systematic review and practice parameter update. Curr Opin Allergy Clin Immunol. 2017;17:286-94.

Meng Y, Wang C, Zhang L. Recent developments and highlights in allergic rhinitis. Allergy. 2019;74: 2320-8.

Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011; 184(10):1125-32.

Spencer S, Köstel Bal S, Egner W, Lango Allen H, Raza SI, Ma CA, et al. Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses. J Exp Med. 2019; 216(9):1986-98.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.

Rincon M, Irvin CG. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci. 2012; 8(9):1281-90.

Zhang Z, Xiao C, Gibson AM, Bass SA, Khurana Hershey GK. EGFR signaling blunts allergen-induced IL-6 production and Th17 responses in the skin and attenuates development and relapse of atopic dermatitis. J Immunol. 2014;192(3):859-66.

Gentile DA, Yokitis J, Angelini BL, Doyle WJ, Skoner DP. Effect of intranasal challenge with interleukin-6 on upper airway symptomatology and physiology in allergic and nonallergic patients. Ann Allergy Asthma Immunol. 2001;86(5):531.

Pfaar O, Klimek L, Jutel M, Akdis CA, Bousquet J, Breiteneder H, et al. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper. Allergy. 2021;76(3): 648-676.

Adegbiji WA, Olajide GT, Olajuyin AO. Pattern of allergic rhinitis among children in Ekiti, Nigeria. Int J Pediatr Otorhinolaryngol. 2018;106:75-9.

Saranz RJ, Lozano A, Lozano NA. Subclinical lower airways correlates of chronic allergic and non-allergic rhinitis. Clin Exp Allergy 2017;47:988-97.

Bocsan IC, Muntean IA, Ureche C. Characterization of patients with allergic rhinitis to ragweed pollen in two distinct regions of Romania. Medicina. 2019; 55:712.

Cardona V, Luengo O, Labrador-Horrillo M. Immunotherapy in allergic rhinitis and lower airway outcomes. Allergy. 2017;72:35-42.

Gao S, Yu L, Zhang J, Li X, Zhou J, Zeng P, Zhang X. Expression and clinical significance of VCAM-1, IL-6, and IL-17A in patients with allergic rhinitis. Ann Palliat Med. 2021;10(4):4516-22.






Original Research Articles